FangyuLei/tatqa huggingface dataset:
Period
Total Number of Shares Purchased (1)
Average Price Paid per Share (2)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (3)
(in millions)
October 1, 2019 - October 31, 2019
—
$
—
$
November 1, 2019 - November 30, 2019
42,800
$209.74
42,800
$103.1
December 1, 2019 - December 31, 2019
50,854
$209.59
50,854
$92.4
Total Fourth Quarter
93,654
$209.66
93,654
$92.4
issuer purchases of equity securities .
in march 2011 our board of directors approved a stock repurchase program pursuant to which we are authorized to repurchase up to $ 1 .
5 billion of our common stock -the “ 2011 buyback ” .
in addition to the 2011 buyback in december 2017 our board of directors approved an additional stock repurchase program pursuant to which we are authorized to repurchase up to $ 2 .
0 billion of our common stock -the “ 2017 buyback ” and together with the 2011 buyback the “ buyback programs ” .
during the three months ended december 31 2019 we repurchased a total of 93654 shares of our common stock for an aggregate of $ 19 .
6 million including commissions and fees pursuant to the 2011 buyback .
there were no repurchases under the 2017 buyback .
the table below sets forth details of our repurchases under the 2011 buyback during the three months ended december 31 2019 .
-1 repurchases made pursuant to the 2011 buyback .
-2 average price paid per share is a weighted average calculation using the aggregate price excluding commissions and fees .
-3 remaining under the 2011 buyback .
we have repurchased a total of 14 .
1 million shares of our common stock under the 2011 buyback for an aggregate of $ 1 .
4 billion including commissions and fees .
we expect to continue to manage the pacing of the remaining $ 2 .
1 billion under the buyback programs in response to general market conditions and other relevant factors .
we expect to fund any further repurchases of our common stock through a combination of cash on hand cash generated by operations and borrowings under our credit facilities .
purchases under the buyback programs are subject to our having available cash to fund repurchases .
under the buyback programs our management is authorized to purchase shares from time to time through open market purchases or in privately negotiated transactions not to exceed market prices and subject to market conditions and other factors .
with respect to open market purchases we may use plans adopted in accordance with rule 10b5-1 under the exchange act in accordance with securities laws and other legal requirements which allows us to repurchase shares during periods when we otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods .
these programs may be discontinued at any time .

Question: What do the company's Buyback Programs authorize the company to do?
Answer: management is authorized to purchase shares from time to time through open market purchases or in privately negotiated transactions not to exceed market prices and subject to market conditions and other factors.
Years Ended December, 31
Years Ended December, 31
Years Ended December, 31
2019
2018
2017
(Dollars in millions, except per share amounts, shares in thousands)
(Dollars in millions, except per share amounts, shares in thousands)
(Dollars in millions, except per share amounts, shares in thousands)
Loss income (Numerator):
Net (loss) income
$(5,269)
(1,733)
1,389
Net (loss) income applicable to common stock for computing basic earnings per common share
(5,269)
(1,733)
1,389
Net (loss) income as adjusted for purposes of computing diluted earnings per common share
$(5,269)
(1,733)
1,389
Shares (Denominator):
Weighted average number of shares:
Outstanding during period
1,088,730
1,078,409
635,576
Non-vested restricted stock
(17,289)
(12,543)
(7,768)
Weighted average shares outstanding for computing basic earnings per common share
1,071,441
1,065,866
627,808
Incremental common shares attributable to dilutive securities:
Shares issuable under convertible securities
—
—
10
Shares issuable under incentive compensation plans
—
—
875
Number of shares as adjusted for purposes of computing diluted (loss) earnings per common share
1,071,441
1,065,866
628,693
Basic (loss) earnings per common share
$(4.92)
(1.63)
2.21
Diluted (loss) earnings per common share(1)
$(4.92)
(1.63)
2.21
-13 -loss earnings per common share .
basic and diluted -loss earnings per common share for the years ended december 31 2019 2018 and 2017 were calculated as follows : .
-1 for the year ended december 31 2019 and december 31 2018 we excluded from the calculation of diluted loss per share 3 .
0 million shares and 4 .
6 million shares respectively potentially issuable under incentive compensation plans or convertible securities as their effect if included would have been anti-dilutive .
our calculation of diluted -loss earnings per common share excludes shares of common stock that are issuable upon exercise of stock options when the exercise price is greater than the average market price of our common stock .
we also exclude unvested restricted stock awards that are antidilutive as a result of unrecognized compensation cost .
such shares were 6 .
8 million 2 .
7 million and 4 .
7 million for 2019 2018 and 2017 respectively .

Question: What is the average annual amount of unvested restricted stock awards that are antidilutive excluded in 2017, 2018 and 2019?
Answer: 4.73
For the Years Ended December 31,
For the Years Ended December 31,
For the Years Ended December 31,
2019
2018
2017
(in thousands)
(in thousands)
(in thousands)
Domestic
$(22,708)
$29,110
$17,120
Foreign
—
(320)
(469)
$(22,708)
$28,790
$16,651
note 13 – income tax .
the domestic and foreign components of loss before income taxes from operations for the years ended december 31 2019 2018 and 2017 are as follows : .

Question: What is the total foreign component of loss before income tax in 2017 and 2018?
Answer: 789
January 3, 2020
December 28, 2018
(in millions)
(in millions)
Computers and other equipment
$259
$233
Leasehold improvements
203
206
Office furniture and fixtures
37
36
Buildings and improvements
23
56
Land
4
40
Construction in progress
104
15
630
586
Less: accumulated depreciation and amortization
(343)
(349)
$ 287
$ 237
note 12 — property plant and equipment .
property plant and equipment net consisted of the following : .
depreciation expense was $ 61 million $ 56 million and $ 55 million for fiscal 2019 2018 and 2017 respectively .

Question: What was the depreciation expense in 2019, 2018 and 2017 respectively?
Answer: $61 million $56 million $55 million
Name
Age
Position (s)
Garo H. Armen
67
Executive Chairman of the Board of Directors
Alexander K. Arrow
49
Chief Financial Officer
Robert B. Stein
69
Director
Khalil Barrage
55
Director
Brian J. Corvese
62
Director
Josh Silverman
49
Director
item 10 .
directors executive officers and corporate governance .
executive officers and directors .
the following sets forth certain information with respect to our executive officers and directors .
garo h .
armen phd executive chairman is one of our founders and joined us in september 2004 .
garo h .
armen is chairman and chief executive officer of agenus inc .
a biotechnology company he co-founded in 1994 .
from mid-2002 through 2004 he also served as chairman of the board of the biopharmaceutical company elan corporation plc which he successfully restructured .
prior to agenus inc .
dr .
armen established armen partners a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the immunex lederle oncology business in 1993 .
earlier he was a senior vice president of research at dean witter reynolds having begun his career on wall street as an analyst and investment banker at ef hutton .
in 2002 dr .
armen founded the children of armenia fund a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural armenian towns to provide immediate and sustainable benefits to children and youth .
he received the ellis island medal of honor in 2004 for his humanitarian efforts and received the sabin humanitarian award from the sabin vaccine institute in 2006 for his achievements in biotechnology and progressing medical research .
dr .
armen was also the ernst & young 2002 new york city biotechnology entrepreneur of the year and received a wings of hope award in 2005 from the melanoma research foundation for his ongoing commitment to the melanoma community .
dr .
armen received a phd in physical chemistry from the graduate center city university of new york after which he worked as a research fellow at brookhaven national laboratories in long island ny .
dr .
armen brings to our board a deep historical and practical knowledge of the business of the company and its technologies as well as years of expertise in the financial and biopharmaceutical arenas .

Question: What is the average age of the directors in the company?
Answer: 58.75
December 31,
December 31,
December 31,
2019
2018
2017
Cash and cash equivalents
$195,760
$303,390
$224,614
Restricted cash
250,081
155,109
129,224
Cash and cash equivalents and restricted cash in Consolidated Statements of Cash Flows
$445,841
$458,499
$353,838
greensky inc .
notes to consolidated financial statements — -continued -united states dollars in thousands except per share data unless otherwise stated .
cash and cash equivalents .
cash includes non-interest and interest-bearing demand deposit accounts with various financial institutions .
cash equivalents include money market mutual fund accounts which are invested in government securities .
we consider all highly liquid investments that mature three months or less from the date of purchase to be cash equivalents .
the carrying amounts of our cash equivalents approximate their fair values due to their short maturities and highly liquid nature .
refer to note 3 for additional information .
at times our cash balances may exceed federally insured amounts and potentially subject the company to a concentration of credit risk .
the company believes that no significant concentration of credit risk exists with respect to these balances based on its assessment of the creditworthiness and financial viability of these financial institutions .
further our cash equivalents may expose us to credit risk ; however we believe this risk is limited as the investments are backed by the full faith and credit of the united states government .
restricted cash .
restricted cash primarily consists of interest-bearing escrow accounts that are required under the terms of the contracts with our bank partners .
restricted cash is typically comprised of three components : -i amounts we have escrowed with bank partners as limited protection to the bank partners in the event of excess bank partner portfolio credit losses ; -ii additional amounts we maintain for certain bank partners based on a contractual percentage of the total interest billed on outstanding deferred interest loans that are within the promotional period less previous finance charge reversal - " fcr " settlements on such outstanding loans ; and -iii certain custodial intransit loan funding and consumer borrower payments that we are restricted from using for our operations .
these custodial balances are not considered in our evaluation of restricted cash usage .
as it relates to our restricted cash escrowed with bank partners we record a liability for the amount of restricted cash we expect to be payable to our bank partners which is accounted for as a financial guarantee .
refer to note 14 for additional information .
the following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total included within the consolidated statements of cash flows as of the dates indicated .

Question: What was the amount of restricted cash in 2017?
Answer: 129,224
Fiscal
Fiscal
2019
2018
Cash and cash equivalents
$305,833
$310,495
Short-term investments
120
120
Working capital
854,507
865,664
additional sources of cash available to us were international currency lines of credit and bank credit facilities totaling $ 26 .
0 million as of september 28 2019 of which $ 20 .
8 million was unused and available .
these unsecured international credit facilities were used in europe and japan during fiscal 2018 .
as of september 28 2019 we had utilized $ 5 .
2 million of the international credit facilities as guarantees in europe .
our ratio of current assets to current liabilities increased to 4 .
6 : 1 at september 28 2019 compared to 3 .
3 : 1 at september 29 2018 .
the increase in our ratio was primarily due to lower income taxes payable partially offset by decreases in our ratio due to lower accounts receivable and inventories .
our cash and cash equivalents short-term investments and working capital are as follows -in thousands : .

Question: Where were the unsecured international credit facilities used in?
Answer: Europe and Japan during fiscal 2018
Lease abandonment charges
Severance & payroll related charges
Total
Balance at March 31, 2018
$—
$—
$—
Restructuring charges
1,034
14,606
15,640
Payments
(540)
(12,642)
(13,182)
Accrual reversals
—
(875)
(875)
Balance at March 31, 2019
$494
$1,089
$1,583
12 .
restructuring .
in fiscal 2019 the company initiated a restructuring plan to increase efficiency in its sales marketing and distribution functions as well as reduce costs across all functional areas .
during the year ended march 31 2019 the company incurred total restructuring charges of $ 14765 .
these restructuring charges relate primarily to severance and related costs associated with headcount reductions and lease abandonment charges associated with two leases .
these charges include $ 2632 of stock- based compensation related to modifications of existing unvested awards granted to certain employees impacted by the restructuring plan .
the activity in the company ’ s restructuring accruals for the year ended march 31 2019 is summarized as follows : .
as of march 31 2019 the outstanding restructuring accruals primarily relate to future severance and lease payments .
-in thousands except per share data .

Question: Why did the company initiate a restructuring plan?
Answer: to increase efficiency in its sales, marketing and distribution functions as well as reduce costs across all functional areas.
Balance Sheet Account
2019
2018
Change
Unbilled receivables
$  183.5
$  169.4
$    14.1
Contract liabilities - current(1)
(840.8)
(714.1)
(126.7)
Deferred revenue - non-current
(33.2)
(29.8)
(3.4)
Net contract assets/(liabilities)
$ (690.5)
$ (574.5)
$ (116.0)
-15 contract balances .
contract balances at december 31 are set forth in the following table : .
the change in our net contract assets / -liabilities from december 31 2018 to december 31 2019 was due primarily to the timing of payments and invoicing relating to saas and pcs renewals partially offset by revenues recognized in the year ended december 31 2019 of $ 674 .
2 related to our contract liability balances at december 31 2018 .
in addition the impact of the 2019 business acquisitions increased net contract liabilities by $ 96 .
2 .
in order to determine revenues recognized in the period from contract liabilities we allocate revenue to the individual deferred revenue or bie balance outstanding at the beginning of the year until the revenue exceeds that balance .
impairment losses recognized on our accounts receivable and unbilled receivables were immaterial in the year ended december 31 2019 .
-1 consists of “ deferred revenue ” and billings in-excess of revenues - “ bie ” .
bie are reported in “ other accrued liabilities ” in our consolidated balance sheets .

Question: How much were the net contract assets/(liabilities), in 2019?
Answer: $ (690.5)
2019
2018
Net sales:    
AMER 
$1,429.3
$1,218.9
APAC 
1,557.2
1,498.0
EMEA 
309.9
281.5
Elimination of inter-segment sales
(132.0)
(124.9)
Total net sales
3,164.4
2,873.5
a discussion of net sales by reportable segment is presented below for the indicated fiscal years -in millions : .
amer .
net sales for fiscal 2019 in the amer segment increased $ 210 .
4 million or 17 .
3 % as compared to fiscal 2018 .
the increase in net sales was driven by a $ 181 .
7 million increase in production ramps of new products for existing customers a $ 13 .
5 million increase in production ramps for new customers and overall net increased customer end-market demand .
the increase was partially offset by a $ 16 .
4 million decrease for end-of-life products and a $ 6 .
0 million reduction due to disengagements with customers .
apac .
net sales for fiscal 2019 in the apac segment increased $ 59 .
2 million or 4 .
0 % as compared to fiscal 2018 .
the increase in net sales was driven by an $ 87 .
3 million increase in production ramps of new products for existing customers and a $ 58 .
1 million increase in production ramps for new customers .
the increase was partially offset by a $ 28 .
4 million reduction due to a disengagement with a customer a $ 7 .
3 million decrease for end-of-life products and overall net decreased customer end-market demand .
emea .
net sales for fiscal 2019 in the emea segment increased $ 28 .
4 million or 10 .
1 % as compared to fiscal 2018 .
the increase in net sales was the result of a $ 20 .
2 million increase in production ramps of new products for existing customers a $ 4 .
2 million increase in production ramps for new customers and overall net increased customer end-market demand .
the increase was partially offset by a $ 6 .
2 million reduction due to a disengagement with a customer .

Question: What was the net sales from EMEA in 2019?
Answer: 309.9
Number of Options
Weighted average exercise price
Weighted average remaining contractual life (years)
Aggregate intrinsic value $
Outstanding, January 1, 2018
1,368,772
$3.12
Granted – 2018
401,099
$9.27
Exercised – 2018
(165,169)
$3.16
Expired – 2018
(50,002)
$5.48
Outstanding, December 31, 2018
1,554,700
$4.63
3.0
Granted – 2019
410,134
$12.28
Exercised – 2019
(251,063)
$3.73
Expired – 2019
(89,550)
$12.55
Outstanding, December 31, 2019
1,624,221
$6.27
2.6
$7,925,643
Exercisable, December 31, 2019
1,143,637
$4.39
1.9
$7,197,053
note 11 – stock compensation .
the company sponsors a stock-based incentive compensation plan known as the 2013 equity compensation plan -the “ plan ” which was established by the board of directors of the company in june 2013 .
a total of 500000 shares were initially reserved for issuance under the plan .
the plan was amended several times since then to eventually increase the authorized shares to 2500000 as of december 31 2019 .
a total of 1624221 shares of common stock underlying options were outstanding at december 31 2019 .
the company had 236614 remaining shares available to grant under the plan at december 31 2019 .
the plan allows the company to grant incentive stock options non-qualified stock options stock appreciation rights or restricted stock .
the incentive stock options are exercisable for up to ten years at an option price per share not less than the fair market value on the date the option is granted .
the incentive stock options are limited to persons who are regular full-time employees of the company at the date of the grant of the option .
non-qualified options may be granted to any person including but not limited to employees independent agents consultants and attorneys who the company ’ s board or compensation committee believes have contributed or will contribute to the success of the company .
non-qualified options may be issued at option prices of less than fair market value on the date of grant and may be exercisable for up to ten years from date of grant .
the option vesting schedule for options granted is determined by the compensation committee of the board of directors at the time of the grant .
the plan provides for accelerated vesting of unvested options if there is a change in control as defined in the plan .
the compensation cost that has been charged against income related to options for the years ended december 31 2019 and 2018 was $ 1687745 and $ 1317904 respectively .
no income tax benefit was recognized in the income statement and no compensation was capitalized in any of the years presented .
the company had the following option activity during the years ended december 31 2019 and 2018 : .
of the options outstanding at december 31 2019 1143637 were exercisable with a weighted average contractual life of 1 .
9 years .

Question: What is the proportion of exercisable options over outstanding options for the year ended in December 31, 2019?
Answer: 0.7
As at 31 December
As at 31 December
2019
2018
RMB’Million
RMB’Million
Operating assets
– Mainland China
345,721
270,373
– Others
168,714
83,962
Investments
– Mainland China and Hong Kong
289,491
254,992
– North America
76,488
44,835
– Europe
29,707
37,451
– Asia excluding Mainland China and Hong Kong
40,139
30,148
– Others
3,726
1,760
953,986
723,521
-a description of segments and principal activities -continued the group also conducts operations in the united states of america - “ united states ” europe and other regions and holds investments -including investments in associates investments in joint ventures fvpl and fvoci in various territories .
the geographical information on the total assets is as follows : .
as at 31 december 2019 the total non-current assets other than financial instruments and deferred tax assets located in mainland china and other regions amounted to rmb311386 million -31 december 2018 : rmb282774 million and rmb136338 million -31 december 2018 : rmb65057 million respectively .
all the revenues derived from any single external customer were less than 10 % of the group ’ s total revenues during the years ended 31 december 2019 and 2018 .

Question: How much did the total non-current assets other than financial instruments as at 31 December 2019 amount to?
Answer: RMB311,386 million
Three months ended August 31,
2019
2018 (1)
Change
(in thousands of dollars, except percentages)
$
$
%
Cash flow from operating activities
304,702
255,438
19.3
Cash flow from investing activities
(144,332)
(194,474)
(25.8)
Cash flow from financing activities
(50,198)
(52,127)
(3.7)
Effect of exchange rate changes on cash and cash equivalents denominated in a foreign currency
(1,405)
(63)
—
Net change in cash and cash equivalents from continuing operations
108,767
8,774
—
Net change in cash and cash equivalent from discontinued operations(2)
—
13,133
(100.0)
Cash and cash equivalents, beginning of the period
447,737
62,818
—
Cash and cash equivalents, end of the period
556,504
84,725
—
cash flow analysis .
-1 fiscal 2018 was restated to comply with ifrs 15 and to reflect a change in accounting policy as well as to reclassify results from cogeco peer 1 as discontinued operations .
for further details please consult the " accounting policies " and " discontinued operations " sections .
-2 for further details on the corporation ' s cash flow attributable to discontinued operations please consult the " discontinued operations " section .
operating activities fiscal 2019 fourth-quarter cash flow from operating activities increased by 19 .
3 % compared to the same period of the prior year mainly from : • higher adjusted ebitda ; • the decreases in income taxes paid and financial expense paid ; and • the increase in changes in non-cash operating activities primarily due to changes in working capital .
investing activities fiscal 2019 fourth-quarter investing activities decreased by 25 .
8 % compared to the same period of the prior year mainly due to the acquisition of spectrum licenses in the canadian broadband services segment in the comparable period of the prior year combined with a decrease in acquisitions of property plant and equipment .

Question: What was the decrease in the investing activities in 2019?
Answer: 25.8%